← FDA DRUG APPROVALS

FDA ANDA · ANDA207226

LEUCOVORIN CALCIUM

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA207226
TYPE
ANDA
ORIGINAL APPROVAL
2018-07-27
LATEST ACTION
2018-07-27
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INTRAMUSCULAR, INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

LEUCOVORIN CALCIUMPrescription
LEUCOVORIN CALCIUM EQ 500MG BASE/50ML (EQ 10MG BASE/ML) · SOLUTION · INTRAMUSCULAR, INTRAVENOUS

Approval history

2018-07-27UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →